Detalhe da pesquisa
1.
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Arterioscler Thromb Vasc Biol
; 41(12): 3005-3014, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706556
2.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Lancet
; 391(10140): 2607-2618, 2018 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945727
3.
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial.
Sci Transl Med
; 13(590)2021 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33883272
4.
Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.
Neuropsychiatr Dis Treat
; 11: 1299-306, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26064048
5.
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
Clin Schizophr Relat Psychoses
; 9(2): 79-87, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25711509
6.
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
Schizophr Res
; 159(2-3): 415-20, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25281992